PT - JOURNAL ARTICLE AU - Andrew P. Hederman AU - Harini Natarajan AU - Joshua A. Wiener AU - Peter F. Wright AU - Evan M. Bloch AU - Aaron A.R. Tobian AU - Andrew D. Redd AU - Joel N. Blankson AU - Amihai Rottenstreich AU - Gila Zarbiv AU - Dana Wolf AU - Tessa Goetghebuer AU - Arnaud Marchant AU - Margaret E. Ackerman TI - SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations AID - 10.1101/2022.09.15.22280000 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.15.22280000 4099 - http://medrxiv.org/content/early/2022/09/18/2022.09.15.22280000.short 4100 - http://medrxiv.org/content/early/2022/09/18/2022.09.15.22280000.full AB - SARS-CoV-2 variants have continuously emerged even as highly effective vaccines have been widely deployed. Reduced neutralization observed against variants of concern (VOC) raises the question as to whether other antiviral antibody activities are similarly compromised, or if they might compensate for lost neutralization activity. In this study, the breadth and potency of antibody recognition and effector function was surveyed in both healthy individuals as well as immunologically vulnerable subjects following either natural infection or receipt of an mRNA vaccine. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observed similar binding and functional breadth for healthy and immunologically vulnerable populations. In contrast, considerably greater functional antibody breadth and potency across VOC was associated with vaccination than prior infection. However, greater antibody functional activity targeting the endemic coronavirus OC43 was noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains that was associated with exposure history. Probing the full-length spike and receptor binding domain (RBD) revealed that antibody-mediated Fc effector functions were better maintained against full-length spike as compared to RBD. This analysis of antibody functions in healthy and vulnerable populations across a panel of SARS-CoV-2 VOC and extending through endemic alphacoronavirus strains suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as the pandemic progresses and novel variants continue to evolve.One Sentence Summary As compared to natural infection with SARS-CoV-2, vaccination drives superior functional antibody breadth raising hopes for candidate universal CoV vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, as well as extramural support from the National Institute of Allergy and Infectious Diseases (R01AI120938, R01AI120938S1 and R01AI128779 to A.A.R.T), National Heart Lung and Blood Institute (K23HL151826 to E.M.B), National Cancer Institute (2 P30 CA 023108-41 to M.E.A.), National Institute of General Medical Sciences (P20-GM113132 BioMT Molecular Tools Core to M.E.A.). A.M. is Research Director at the F.R.S., FNRS, Belgium.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Subjects provided informed written consent and studies were reviewed and approved by IRBs at individual collection sites and Dartmouth.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors